Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06FGJ
|
|||
| Former ID |
DIB000195
|
|||
| Drug Name |
Protexia
|
|||
| Synonyms |
RBChE; PEG-rBChE; PEGylated butyrylcholinesterase (recombinant human, nerve agent exposure), PharmAthene
Click to Show/Hide
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 1 | [1] | |
| Company |
Nexia Biotechnologies Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cholinesterase (BCHE) | Target Info | Modulator | [2] |
| Panther Pathway | Muscarinic acetylcholine receptor 1 and 3 signaling pathway | |||
| Muscarinic acetylcholine receptor 2 and 4 signaling pathway | ||||
| Nicotinic acetylcholine receptor signaling pathway | ||||
| WikiPathways | Irinotecan Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00744146) First Time in Human Study of Protexia. U.S. National Institutes of Health. | |||
| REF 2 | In vitro and in vivo characterization of recombinant human butyrylcholinesterase (Protexia) as a potential nerve agent bioscavenger. Chem Biol Interact. 2005 Dec 15;157-158:363-5. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.